Dall-E Mini, the AI-powered text-to-image generator has taken over the internet. With its ability to render nearly anything your meme-loving heart desires, anyone can make their dreams come true.
DALL-E 2, a portmanteau of Salvador Dali, the surrealist and Wall-E, the Pixar robot, was created by OpenAI and is not widely available; it creates far cleaner imagery and was recently used to launch Cosmpolitan’s first AI-generated cover. The art world has been one of the first industries to truly embrace AI.
The open-sourced miniature version is what’s responsible for the memes. Programmer Boris Dayma wants to make AI more accessible; he built the Dall-E Mini program as part of a competition held by Google and an AI community called Hugging Face.
And with great technology, comes great memes. Typing a short phrase into Dall-E Mini will manifest 9 different amalgamations, theoretically shaping into reality the strange images you’ve conjured. Its popularity leads to too much traffic, often resulting in an error that can be fixed by refreshing the page or trying again later.
If you want to be a part of the creation of AI-powered engines, it all starts with code. CodeAcademy explains that Dall-E Mini is a seq2seq model, “typically used in natural language processing (NLP) for things like translation and conversational modeling.” CodeAcademy’s Text Generation course will teach you how to utilize seq2seq, but they also offer opportunities to learn 14+ coding languages at your own pace.
You can choose the Machine Learning Specialist career path if you want to become a Data Scientist who develops these types of programs, but you can also choose courses by language, subject (what is cybersecurity?) or even skill - build a website with HTML, CSS, and more.
CodeAcademy offers many classes for free as well as a free trial; it’s an invaluable resource for giving people of all experience levels the fundamentals they need to build the world they want to see.
As for Dall-E Mini, while some have opted to create beauty, most have opted for memes. Here are some of the internet’s favorites:
pic.twitter.com/DbLoe1s00c
— Weird Dall-E Mini Generations (@weirddalle) June 8, 2022
pic.twitter.com/cxtliOrlHz
— Weird Dall-E Mini Generations (@weirddalle) June 12, 2022
no fuck every other dall-e image ive made this one is the best yet pic.twitter.com/iuFNm4UTUM
— bri (@takoyamas) June 10, 2022
pic.twitter.com/rEBHoWR7lH
— Weird Dall-E Mini Generations (@weirddalle) June 12, 2022
pic.twitter.com/RSZaCIDVV7
— Chairman George (@superbunnyhop) June 9, 2022
back at it again at the DALL•E mini pic.twitter.com/iPGsaMThBC
— beca. ⚢ (@dorysief) June 9, 2022
There’s no looking back now, not once you’ve seen Pugachu; artificial intelligence is here to stay.
Connecticut Approves Chronic Pain as Qualifying Condition to Medical Cannabis Program
There are now 38 ailments that qualify a patient for medical cannabis in the State of Connecticut.
Connecticut's medical cannabis program is about to get a lot bigger!
Last September the Regulation Review Committee approved two new conditions for the State's eight-year-old medical marijuana program. These recommendations were made by the Board of Physicians and Commissioner of Consumer Protection. By adding chronic pain and Ehlers-Danlos Syndrome to the list of qualifying conditions, there are now 38 ailments that qualify a patient for medical cannabis in the State of Connecticut. Below is a breakdown of approved conditions for adults over 18 years of age, as well as patients under the age of 18.
For Adults, Debilitating Medical Conditions Include:
- Cancer (Effective 2012)
- Glaucoma (Effective 2012)
- Positive status for HIV or Acquired Immune Deficiency Syndrome (Effective 2012)
- Parkinson's Disease (Effective 2012)
- Multiple Sclerosis (Effective 2012)
- Damage to the Nervous Tissue Of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
- Epilepsy (Effective 2012)
- Cachexia (Effective 2012)
- Wasting Syndrome (Effective 2012)
- Crohn's Disease (Effective 2012)
- Post-Traumatic Stress Disorder (Effective 2012)
- Sickle Cell Disease (Effective 2016)
- Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)
- Severe Psoriasis and Psoriatic Arthritis (Effective 2016)
- Amyotrophic Lateral Sclerosis (Effective 2016)
- Ulcerative Colitis (Effective 2016)
- Complex Regional Pain Syndrome, Type I and Type II (Effective 2016)
- Cerebral Palsy (Effective 2016)
- Cystic Fibrosis (Effective 2016)
- Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
- Terminal Illness Requiring End-Of-Life Care (Effective 2016)
- Uncontrolled Intractable Seizure Disorder (Effective 2016)
- Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)
- Severe Rheumatoid Arthritis (Effective 2018)
- Post Herpetic Neuralgia (Effective 2018)
- Hydrocephalus with Intractable Headache (Effective 2018)
- Intractable Headache Syndromes (Effective 2018)
- Neuropathic Facial Pain (Effective 2018)
- Muscular Dystrophy (Effective 2018)
- Osteogenesis Imperfecta (Effective 2018)
- Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)
- Interstitial Cystitis (Effective 2019)
- MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)
- Vulvodynia and Vulvar Burning (Effective 2019)
- Intractable Neuropathic Pain that is Unresponsive to Standard Medical Treatments (Effective 2019)
- Tourette Syndrome (Effective 2019)
- Ehlers-Danlos Syndrome (Effective 2020)
- Cerebral Palsy (Effective 2016)
- Cystic Fibrosis (Effective 2016)
- Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
- Severe Epilepsy (Effective 2016)
- Terminal Illness Requiring End-Of-Life Care (Effective 2016)
- Uncontrolled Intractable Seizure Disorder (Effective 2016)
- Muscular Dystrophy (Effective 2018)
- Osteogenesis Imperfecta (Effective 2018)
- Intractable Neuropathic Pain that is Unresponsive to Standard Medical Treatments (Effective 2018)
- Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)
- Ehlers-Danlos Syndrome
